2-decade revenue high; PAT surges 405%, FY31 target on execution
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
First formal guidance; Q2 numbers delivered as stated; H1 turnaround achieved (₹36 Cr loss to ₹8 Cr profit).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q2 delivery: revenue +25% YoY, PAT +405% YoY; credible FY31 aspiration (INR10K+ Cr at 20%+ EBITDA) with concrete capex pipeline. Key risk: commodity cycle volatility and capex execution.
₹1358 Cr
Revenue · +25.3% YoY₹79 Cr
Reported PAT · +405.3% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue INR1,358 Cr vs INR1,083 Cr prior year
METDelivered result: INR1,357.5 Cr, YoY +25.3%
EBITDA INR222 Cr (15.74% margin)
METImplied from results; EBITDA margin improved from 11.6% YoY
PAT INR79 Cr from INR16 Cr prior year
METDelivered: INR82.6 Cr (minor rounding difference in call vs filing)
H1 sales INR2,559.63 Cr, highest in two decades
METSpecific historical claim; corroborated by Q2 FY27 delivery
Earnings quality
What changed since the last call
Profitability turnaround
UpgradeH1 FY26 loss ₹36 Cr swung to H1 FY27 profit ₹8 Cr; Q2 PAT ₹79 Cr from ₹16 Cr (405% YoY).
Renewable energy mix
UpgradeRenewable penetration increased from 38% (Q2 FY26) to 55% (Q2 FY27); power cost trajectory improved.
Value-added product shift
UpgradeValue-added products now 61% of Q2 sales vs lower prior year; command pricing premiums (chlorotoluene +100% YoY).
Domestic demand acceleration
UpgradeDomestic sales +29% YoY in Q2; exports +14%; market diversification improving.
Chlorine integration progress
NeutralNow 45% of capacity; target 75% by FY29 as HCl units commission.
The Q&A
Analysts pressed on capacity utilization splits, chlorine realization impact, power cost trajectory, capex details, and product-specific volumes. Management provided operational metrics (92% utilization, 45% chlorine integration, 55% renewable) but appropriately deferred commercially sensitive data to investor presentations.
Capacity utilization — Saket Kapoor, Kapoor & Co
Answered92% average; Chlorotoluene ramp to ~90%; grid disturbances affected some periods; plants with higher realization performing well
Chlorine realization — Saket Kapoor, Kapoor & Co
PartialPositive Q2 outcome; chlorine prices substantially negative which improved ECU levels significantly
Power cost trajectory — Saket Kapoor, Kapoor & Co
AnsweredSlight H1 increase vs budget but INR0.57/kWh reduction vs H1 FY26; DISCOM impact INR0.45; renewable share increased; long-term target INR6
Value-added product contribution — Nirav Jimudia, Anvil Wealth
AnsweredValue-added 61% of Q2 sales; chlorotoluene strong pricing uplift, phosphoric acid +44%, hydrogen peroxide +31%, caustic +10%
Caustic export market — Resham Jain, VVD Asset Managers
AnsweredIndia #3 caustic producer; European capacity phasing; India well-positioned for US and Asian markets; solid and liquid caustic exports growing
Chloromethane dynamics — Resham Jain, VVD Asset Managers
PartialR22 phasing near completion; R132 many capacities coming; methylene chloride major component; promising portfolio in current market
Product volumes — Vipul Shah, Sumangal Investments
DodgedVolume details shared separately; product revenue share in investor presentation; capex details with Board approvals
Capex and funding — Vipul Shah, Sumangal Investments
PartialBoard approved projects with specific numbers in investor presentation; mix of internal accruals and borrowings; difficult to give precise number now
Guidance
FY27-28 capex: 200 TPD caustic, 120 TPD HCl, food phosphoric acid expansion
HighBoard approved; timelines Dec 2026 (caustic) and Jan 2027 (HCl); projects in pipeline with identified suppliers
Chlorine integration to 75% by FY29 (2-3 years)
MediumCurrently 45%; depends on HCl unit commissioning and downstream integration; long-term capex plan in place
FY31 aspiration: INR10,000+ Cr revenue with 20%+ EBITDA
MediumMedium-term aspiration under Project Ahvaan; depends on project execution and commodity cycle; not formal guidance
Target EBITDA margins 20%+ by FY31 from current 16%
MediumDrivers: chlorine integration, renewable energy cost reduction, asset productivity, value-added product mix shift
Power cost reduction to INR6/kWh by Mar 2027 from INR6.95/kWh
MediumRenewable expansion to 60%; long-term target <INR6/kWh with 80% RE penetration by FY31
FY27-28: 200 TPD caustic flaking, 120 TPD HCl, food phosphoric acid capex
HighDahej 200 TPD Dec 2026; HCl Jan 2027; Board approved, funding from accruals + borrowings
FY28-29: Chlorotoluene downstream, KOH, electronic-grade H2O2 projects
MediumProject timeline FY28, funding in progress; Board seeking approvals for specific capex amounts
Risks the call surfaced
Commodity price volatility
MediumCaustic soda and chlorine are commodity chemicals highly dependent on global industrial production cycles. Q2 chlorine prices were 'substantially negative' impacting realization.
Capex execution risk
MediumMultiple projects with tight timelines: 200 TPD caustic flaking (Dec 2026), 120 TPD HCl (Jan 2027), Chlorotoluene, food phosphoric acid. Delays would push margin improvement targets.
Power cost inflation
MediumPower 20-30% of COGS; DISCOM hikes (INR0.45/kWh observed) and grid disturbances impact quarterly profitability. Currently 43% grid-dependent.
Competitive capacity additions
MediumManagement mentioned 'two large private corporates coming up with huge facilities of caustic soda in the near or medium term.' This could increase market competition and pressure pricing.
Early-stage venture risks
MediumGNAL (caustic JV with NALCO) moved to profitability but higher quarterly volatility. Hydrazine sole Indian producer but pilot/commercialization stage with uncertain timeline.
Management
Score 7/10. Clear on strategic direction and operational metrics (92% capacity utilization, 55% renewable energy, 45% chlorine integration); transparent on challenges (cyclical nature, power costs, capex execution risk); appropriately guards commercially sensitive details. H1 FY27 turnaround delivered (loss to ₹8 Cr profit); Q2 targets hit (revenue, EBITDA, PAT); capex projects Board-approved with Dec 2026-Jan 2027 timelines; renewable energy penetration increased (38% to 55%); first guidance cycle, track record pending.
1 · Dec 2026
200 TPD caustic flaking facility commissioned at Dahej
2 · Jan 2027
120 TPD HCl synthesis unit commissioned
3 · Mar 2027
Power cost INR6/kWh with 60% renewable energy
Key risk: commodity cycle volatility and capex execution.
Informational and educational content only. Not investment advice.